Nothing Special   »   [go: up one dir, main page]

PE20141908A1 - Anticuerpos cd47 y metodos de uso los mismos - Google Patents

Anticuerpos cd47 y metodos de uso los mismos

Info

Publication number
PE20141908A1
PE20141908A1 PE2014001225A PE2014001225A PE20141908A1 PE 20141908 A1 PE20141908 A1 PE 20141908A1 PE 2014001225 A PE2014001225 A PE 2014001225A PE 2014001225 A PE2014001225 A PE 2014001225A PE 20141908 A1 PE20141908 A1 PE 20141908A1
Authority
PE
Peru
Prior art keywords
seq
established
sequence
cdr1
cdr2
Prior art date
Application number
PE2014001225A
Other languages
English (en)
Inventor
Brendan Eckelman
John Timmer
Amir Razai
Quinn Deveraux
Kyle Jones
Peter L Nguy
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141908(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of PE20141908A1 publication Critical patent/PE20141908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL AISLADO QUE SE UNE A CD47 O UN FRAGMENTO INMUNOLOGICAMENTE ACTIVO DEL MISMO, EL CUAL COMPRENDE: A) UNA REGION DE CADENA PESADA VARIABLE (VH) QUE CONTIENE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID N�: 5 A 30; B) UNA REGION DE CADENA LIVIANA VARIABLE (VL) QUE CONTIENE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LA SEQ ID N�: 31 A 47; C) UNA SECUENCIA DE i) CDR1 DE VH ESTABLECIDA EN LA SEQ ID N�: 50, 57, 58, 59, ENTRE OTROS, ii) CDR2 DE VH ESTABLECIDA EN LA SEQ ID N�: 51, 72, 73, 74, ENTRE OTROS, Y iii) CDR3 DE VH ESTABLECIDA EN LA SEQ ID N�: 52 O 77; Y D) UNA SECUENCIA DE i) CDR1 DE VL ESTABLECIDA EN LA SEQ ID N�: 53, 67 O 68, ii) CDR2 DE VL ESTABLECIDA EN LA SEQ ID N�: 54, 69, 70 O 71, Y iii) CDR3 DE VL ESTABLECIDA EN LA SEQ ID N�: 55; EN DONDE EL ANTICUERPO PROMUEVE LA FAGOCITOSIS MEDIADA POR MACROFAGO DE UNA CELULA QUE EXPRESA CD47 Y NO PROVOCA UN NIVEL SIGNIFICATIVO DE AGLUTINACION DE CELULAS DESPUES DE SU ADMINISTRACION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER
PE2014001225A 2012-02-06 2013-02-06 Anticuerpos cd47 y metodos de uso los mismos PE20141908A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261595216P 2012-02-06 2012-02-06
US201261659752P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
PE20141908A1 true PE20141908A1 (es) 2014-12-21

Family

ID=48947976

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001225A PE20141908A1 (es) 2012-02-06 2013-02-06 Anticuerpos cd47 y metodos de uso los mismos

Country Status (35)

Country Link
US (4) US9045541B2 (es)
EP (2) EP2812443B1 (es)
JP (1) JP6273212B2 (es)
KR (2) KR102338833B1 (es)
CN (2) CN111533804A (es)
AU (1) AU2013217114B2 (es)
BR (1) BR112014019331A2 (es)
CA (1) CA2863834A1 (es)
CL (1) CL2014002086A1 (es)
CO (1) CO7111273A2 (es)
CR (1) CR20140406A (es)
CY (1) CY1121911T1 (es)
DK (1) DK2812443T3 (es)
EA (1) EA034778B1 (es)
EC (1) ECSP14016994A (es)
ES (1) ES2743203T3 (es)
HK (1) HK1205195A1 (es)
HR (1) HRP20191500T1 (es)
HU (1) HUE13746964T2 (es)
IL (1) IL233934B (es)
LT (1) LT2812443T (es)
ME (1) ME03512B (es)
MX (1) MX360772B (es)
MY (1) MY169341A (es)
NZ (1) NZ628314A (es)
PE (1) PE20141908A1 (es)
PH (1) PH12014501758A1 (es)
PL (1) PL2812443T3 (es)
PT (1) PT2812443T (es)
RS (1) RS59159B1 (es)
SG (2) SG11201404638SA (es)
SI (1) SI2812443T1 (es)
UA (1) UA116772C2 (es)
WO (1) WO2013119714A1 (es)
ZA (1) ZA201405864B (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2429574T3 (pl) 2009-05-15 2015-12-31 Univ Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
SG11201404638SA (en) 2012-02-06 2014-09-26 Inhibrx Llc Cd47 antibodies and methods of use thereof
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
EP2953643B1 (en) * 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
DK2970493T3 (da) * 2013-03-15 2019-05-13 Univ Leland Stanford Junior Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
EP3828203B1 (en) * 2013-12-17 2024-04-24 MHS Care - Innovation LLC Compositions and methods for treating fatty tissue buildup
JP6560682B2 (ja) * 2014-01-08 2019-08-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
BR112017010303A2 (pt) 2014-11-18 2018-05-15 Janssen Pharmaceutica Nv anticorpos anti-cd47, métodos e usos
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
JP6959865B2 (ja) 2015-01-21 2021-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TWI719966B (zh) * 2015-03-04 2021-03-01 美商索倫多醫療公司 結合ｃｄ４７之抗體治療劑
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
CA2999277A1 (en) * 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use
SI3402820T1 (sl) 2016-01-11 2021-04-30 Forty Seven, Inc. Humanizirana, mišja ali himerna monoklonska protitelesa proti-CD47
PL3442578T3 (pl) 2016-04-15 2022-06-20 The Board Of Trustees Of The Leland Stanford Junior University Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów
TW201741340A (zh) * 2016-05-09 2017-12-01 賽基公司 Cd47抗體及使用其之方法
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
AR108975A1 (es) * 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
MX2019004691A (es) * 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Anticuerpos monoclonales cd47 novedosos y sus usos.
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3534964A4 (en) * 2016-11-03 2020-07-15 Trillium Therapeutics Inc. IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
WO2018095428A1 (zh) * 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof
WO2018175790A1 (en) * 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
BR112019020940A2 (pt) 2017-04-11 2020-05-05 Inhibrx Inc construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
JP2020512843A (ja) 2017-04-14 2020-04-30 トルニネ， インコーポレイテッド 免疫調節ポリヌクレオチド、その抗体コンジュゲート、及びそれらの使用方法
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
FI3658141T3 (fi) 2017-07-24 2023-03-02 Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella
NZ761568A (en) * 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
SG11202001425TA (en) 2017-08-18 2020-03-30 Ultrahuman Four Ltd Binding agents
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
EP3704157A1 (en) 2017-11-01 2020-09-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
CA3044097A1 (en) * 2017-11-10 2019-05-16 I-Mab Fusion proteins containing cd47 antibodies and cytokines
CA3083946A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
AU2019212674A1 (en) * 2018-01-24 2020-09-03 Nanjing Legend Biotech Co., Ltd. Anti-CD47 antibodies that do not cause significant red blood cell agglutination
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
CN110526972A (zh) * 2018-05-25 2019-12-03 江苏恒瑞医药股份有限公司 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
CN110577597B (zh) 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CN112566662A (zh) * 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 针对cd47的阻断抗体及其使用方法
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
CN112601544A (zh) * 2018-07-05 2021-04-02 三钰生物科技股份有限公司 人类抗cd47抗体及其用途
CN112601762B (zh) * 2018-08-31 2023-04-04 南京圣和药业股份有限公司 抗cd47抗体及其应用
WO2020088580A1 (en) * 2018-10-31 2020-05-07 I-Mab Biopharma Co., Ltd. Novel cd47 antibodies and methods of using same
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN111253488A (zh) * 2018-12-03 2020-06-09 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
TW202045550A (zh) 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
JP7561775B2 (ja) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
AU2020296785A1 (en) * 2019-06-19 2022-01-20 Lepu Biopharma Co., Ltd. Anti-CD47 antibodies and uses thereof
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CN110256565B (zh) * 2019-08-02 2021-03-23 天津大学 抗cd47纳米抗体突变体及其应用
GB2628935A (en) 2019-09-03 2024-10-09 Myeloid Therapeutics Inc Methods and compositions for genomic integration
ES2975528T3 (es) 2019-09-18 2024-07-08 Lamkap Bio Alpha AG Anticuerpos biespecíficos contra ceacam5 y cd3
CA3156160A1 (en) * 2019-09-27 2021-04-01 Beijing Starmab Biomed Technology Ltd. Monospecific and multi-specific antibodies
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
JP7520972B2 (ja) * 2019-10-25 2024-07-23 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｃｄ４７抗体及びその使用
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CR20220303A (es) 2019-12-24 2022-09-02 Gilead Sciences Inc Compuestos moduladores de la diacilglicerol quinasa
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2021170082A1 (zh) 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
CA3172449A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN114057876A (zh) * 2020-07-31 2022-02-18 百奥泰生物制药股份有限公司 Cd47抗体及其应用
WO2022076987A1 (en) 2020-10-07 2022-04-14 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
EP4237451A1 (en) 2020-11-02 2023-09-06 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR20220080375A (ko) 2020-12-07 2022-06-14 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023277281A1 (ko) 2021-06-30 2023-01-05 (주)이노베이션바이오 Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4245756B1 (en) 2022-03-17 2024-10-09 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124107A2 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024177978A1 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb3 engager cells
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN117004700A (zh) * 2023-10-07 2023-11-07 北京爱博生生物技术有限公司 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
ATE196313T1 (de) 1993-06-04 2000-09-15 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997007671A1 (fr) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Animal chimerique et procede de constitution
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
KR20040106585A (ko) * 1997-09-11 2004-12-17 츄가이 세이야꾸 가부시키가이샤 아포토시스를 유기하는 모노클로날 항체
WO2000053634A1 (fr) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2002092784A2 (en) * 2001-05-15 2002-11-21 Emory University POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47
KR100454414B1 (ko) 2001-06-25 2004-10-26 주식회사 진생사이언스 산소를 이용한 개량 홍삼의 제조 방법
AU2003276832A1 (en) 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
WO2003102215A2 (en) 2002-05-31 2003-12-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and isolating stem cells and cancer stem cells
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) * 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
CA2546465A1 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
TW200540186A (en) 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
JP4928443B2 (ja) 2004-05-07 2012-05-09 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル インスリン様成長因子ｉを増強または阻害するための方法
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
US7728880B2 (en) 2004-06-25 2010-06-01 Qualcomm Incorporated Automatic white balance method and apparatus
US7807160B2 (en) 2005-08-31 2010-10-05 Schering Corporation Engineered anti-IL-23 antibodies
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
BRPI0813985B1 (pt) * 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
KR100962704B1 (ko) 2008-07-02 2010-06-11 유상규 일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법
AU2009281713B9 (en) 2008-08-14 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Anti-IL-12/IL-23 antibodies
CA3050455A1 (en) * 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
WO2011059972A1 (en) 2009-11-10 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell surface marker expression in hematopoietic stem cells and progenitors for the diagnosis, prognosis, and treatment of myelodysplastic syndromes
DK2569013T3 (da) 2010-05-14 2017-02-13 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer til cd47
WO2012021867A2 (en) 2010-08-13 2012-02-16 The Johns Hopkins University A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors
WO2012088309A1 (en) 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
PL2804617T3 (pl) 2012-01-17 2020-11-30 The Board Of Trustees Of The Leland Stanford Junior University Reagenty sirp-alfa o wysokim powinowactwie
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
SG11201404638SA (en) * 2012-02-06 2014-09-26 Inhibrx Llc Cd47 antibodies and methods of use thereof
RU2015106333A (ru) 2012-08-31 2016-10-27 Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл Моноклональные антитела для стимуляции или ингибирования инсулиноподобного фактора роста 1 (igf-1)
EP2953643B1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
WO2013119714A1 (en) 2013-08-15
SI2812443T1 (sl) 2019-10-30
EA201400875A1 (ru) 2015-01-30
US20160251435A1 (en) 2016-09-01
EA034778B1 (ru) 2020-03-19
EP2812443A4 (en) 2015-11-04
ES2743203T3 (es) 2020-02-18
CN104271757A (zh) 2015-01-07
MX2014009427A (es) 2015-05-11
ZA201405864B (en) 2015-11-25
US20210317205A1 (en) 2021-10-14
DK2812443T3 (da) 2019-08-26
NZ628314A (en) 2017-01-27
PT2812443T (pt) 2019-09-05
PH12014501758B1 (en) 2014-11-10
HRP20191500T1 (hr) 2019-11-29
KR102100388B1 (ko) 2020-04-13
MY169341A (en) 2019-03-21
US9045541B2 (en) 2015-06-02
KR20150008049A (ko) 2015-01-21
ECSP14016994A (es) 2015-09-30
IL233934B (en) 2022-04-01
AU2013217114B2 (en) 2017-03-30
KR102338833B1 (ko) 2021-12-13
HUE13746964T2 (hu) 2020-01-28
HK1205195A1 (en) 2015-12-11
SG11201404638SA (en) 2014-09-26
ME03512B (me) 2020-04-20
CY1121911T1 (el) 2020-10-14
EP3578569A1 (en) 2019-12-11
CO7111273A2 (es) 2014-11-10
CN111533804A (zh) 2020-08-14
PL2812443T3 (pl) 2020-01-31
US20130224188A1 (en) 2013-08-29
EP2812443B1 (en) 2019-05-29
CN104271757B (zh) 2020-06-09
LT2812443T (lt) 2019-09-10
AU2013217114A1 (en) 2014-09-18
CL2014002086A1 (es) 2015-02-27
CR20140406A (es) 2014-12-10
UA116772C2 (uk) 2018-05-10
MX360772B (es) 2018-11-15
JP2015508072A (ja) 2015-03-16
SG10201700160RA (en) 2017-03-30
IL233934A0 (en) 2014-09-30
KR20200040897A (ko) 2020-04-20
BR112014019331A8 (pt) 2018-01-16
CA2863834A1 (en) 2013-08-15
JP6273212B2 (ja) 2018-01-31
US20150238604A1 (en) 2015-08-27
PH12014501758A1 (en) 2014-11-10
RS59159B1 (sr) 2019-10-31
BR112014019331A2 (pt) 2022-07-12
EP2812443A1 (en) 2014-12-17
US9663575B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20131209A1 (es) Anticuerpos anti-fap
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
PE20161390A1 (es) Anticuerpos multiespecificos
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
PE20190737A1 (es) Anticuerpos anti-cd27
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20142407A1 (es) Formulacion de anticuerpos
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos

Legal Events

Date Code Title Description
FC Refusal